UBS Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.47M	Sell	158,120 -73,172	-32%	-$637K	﹤0.01%	5242
2025 Q4	$1.73M	Buy	231,292 +136,392	+144%	+$1.38M	﹤0.01%	5097
2025 Q3	$825K	Sell	94,900 -1,619	-2%	-$9.68K	﹤0.01%	5723
2025 Q2	$358K	Sell	96,519 -139,926	-59%	-$492K	﹤0.01%	6290
2025 Q1	$764K	Buy	236,445 +138,881	+142%	+$654K	﹤0.01%	5513
2024 Q4	$543K	Buy	97,564 +17,275	+22%	+$136K	﹤0.01%	5776
2024 Q3	$868K	Buy	80,289 +13,149	+20%	+$218K	﹤0.01%	4778
2024 Q2	$1.41M	Sell	67,140 -307,050	-82%	-$7.7M	﹤0.01%	4104
2024 Q1	$11.9M	Buy	374,190 +288,139	+335%	+$7.35M	﹤0.01%	2125
2023 Q4	$1.74M	Buy	86,051 +41,154	+92%	+$541K	﹤0.01%	3970
2023 Q3	$572K	Sell	44,897 -8,953	-17%	-$150K	﹤0.01%	4557
2023 Q2	$973K	Buy	53,850 +1,451	+3%	+$26.7K	﹤0.01%	4280
2023 Q1	$901K	Buy	52,399 +11,671	+29%	+$227K	﹤0.01%	4210
2022 Q4	$905K	Buy	+40,728	New	+$629K	﹤0.01%	4167
2022 Q3	–	Sell	-35	Closed	–	–	10504
2022 Q2	$0	Sell	35 -70,199	-100%	-$682K	﹤0.01%	10491
2022 Q1	$1.06M	Buy	70,234 +884	+1%	+$13.9K	﹤0.01%	4034
2021 Q4	$1.52M	Buy	69,350 +68,094	+5,421%	+$1.67M	﹤0.01%	3997
2021 Q3	$34K	Buy	+1,256	New	+$35.8K	﹤0.01%	6640
2021 Q2	–	Sell	-20,592	Closed	-$893K	–	9494
2021 Q1	$893K	Buy	+20,592	New	+$912K	﹤0.01%	4376